Hansoh Pharmaceutical (03692.HK) Receives NMPA Approval to Initiate Clinical Trials for HS-20118 Tablets in Moderate-to-Severe Plaque Psoriasis

Hansoh Pharma (03692) announced that HS-20118 Tablets, a Class 1 innovative drug independently developed by the Group, has received clinical trial approval from the National Medical Products Administration (NMPA) of China. The drug is expected to be tested in clinical trials for moderate to severe plaque psoriasis.